David Calvet Canut։ Efdoralprin Alfa Shows Promise in Alpha 1 Antitrypsin Deficiency
David Calvet Canut, Chief Financial Officer at Rudder Marine Services and Ship Repairs S.L, shared a post on LinkedIn:
”A potential breakthrough for Alpha-1 Antitrypsin Deficiency (AATD) has emerged from Sanofi’s Phase 2 ElevAATe clinical trial. The investigational treatment, efdoralprin alfa, has shown promising results for adults living with pulmonary emphysema caused by AATD.
Unlike current therapies that rely on donated plasma, efdoralprin alfa is a recombinant protein produced in the laboratory, designed to mimic the natural AAT protein that protects the lungs from inflammatory damage. This could represent a significant advancement towards a more sustainable, supply-independent treatment option.
Key findings from the ElevAATe trial include:
- Patients achieved normal, stable levels of functional AAT protein, significantly higher than those seen with standard plasma-derived treatment.
- A greater proportion of days were spent at protective protein levels.
- The treatment was well tolerated, with a safety profile comparable to existing therapies.
- It is effective when administered every three to four weeks, potentially offering a more convenient treatment schedule.
Dr. Igor Barjaktarevic, lead investigator at UCLA, noted that achieving normal AAT levels without relying on plasma donations ‘would be a very positive change’ for patients living with Alpha-1.
Efdoralprin alfa has already received both Fast Track and Orphan Drug designations from the FDA, indicating the unmet need this treatment aims to address. A long-term safety follow-up study (ElevAATe OLE) is now underway.”
Stay updated with Hemostasis Today.
-
Apr 20, 2026, 05:38Doreen Su-Yin Tan։ Moving Toward Precision in Antiplatelet Therapy 2026 SCSASM2026 Highlights
-
Apr 20, 2026, 05:36Emma Groarke: Evidence-Based Guidelines for the Management of Acquired Aplastic Anemia
-
Apr 20, 2026, 04:27Tareq Abadl: Can Vitamin C Trick a Glucose Reading?
-
Apr 20, 2026, 04:24Tagreed Alkaltham: Motivational Drivers of Voluntary Blood Donation
-
Apr 20, 2026, 01:13Konstantin Yenkoyan: Are We Targeting Alzheimer’s Disease at the Right Time and in the Right Place?
-
Apr 20, 2026, 00:59David McIntosh: The Vital Role of Blood and Plasma Donors in Medicine Supply
-
Apr 20, 2026, 00:38Strengthening Care in Burundi – WFH
-
Apr 20, 2026, 00:20Salih Ehsan: Why Are HbA2 Levels Stable in Thalassemia Minor During Severe Iron Deficiency?
-
Apr 20, 2026, 00:07Karen Zohrabyan: Honored to Be Speaking at CSI Frankfurt 2026